MAPT and Alzheimer disease: 2025), which may reflect methodological variability. Moreover, we did not include other core AD biomarkers, such as tau or CSF measures, nor did we incorporate metabolic indicators that have been associated with both cortical and salivary tracer uptake in prior studies (Gomez et al. 2018; Hida et al. 2012).